Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer - Wikidata - wikimedia - TriplyDB

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer

http://www.wikidata.org/entity/Q36632306

about

Imiquimod - Its role in the treatment of cutaneous malignancies Neutralizing tumor-promoting chronic inflammation: a magic bullet?The Yin and Yang of Toll-like receptors in cancer The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation Clinical significance of tumor-infiltrating lymphocytes in breast cancer AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ Combinations of immunotherapy and radiation in cancer therapy.A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis.The Immunomodulatory Small Molecule Imiquimod Induces Apoptosis in Devil Facial Tumour Cell Lines Current clinical trials testing combinations of immunotherapy and radiation.Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy.Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?TLR agonists: our best frenemy in cancer immunotherapy A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice Toll-like receptors in prostate infection and cancer between bench and bedside Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.Toll-like receptor agonists: a patent review (2011 - 2013).Modes of action of TLR7 agonists in cancer therapy.In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.In situ vaccination for the treatment of cancer.Biological Response Modifier in Cancer Immunotherapy.Intratumoral Delivery of Immunotherapy-Act Locally, Think Globally.Anti-tumor Activity of Toll-Like Receptor 7 Agonists.TLR7 agonist induced repression of hepatocellular carcinoma via the TLR7-IKK-NF-κB-IL6 signaling pathway.MAGE-specific T cells detected directly ex-vivo correlate with complete remission in metastatic breast cancer patients after sequential immune-endocrine therapy.The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer.Antigen Cross-Presentation and T-Cell Cross-Priming In Cancer Immunology And Immunotherapy.TLR Agonists as Adjuvants for Cancer Vaccines.Trial Watch: Toll-like receptor agonists for cancer therapy.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.The TLR-specific adjuvants R-848 and CpG-B endorse the immunological reaction of neonatal antigen-presenting cells.Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.Radiation and Anti-Cancer Vaccines: A Winning Combination.Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.Tumor Associated Macrophages as Therapeutic Targets for Breast Cancer.Harnessing the immune system in the battle against breast cancer.

P2860

Q26796536-6CB7104B-D050-4BA6-ACD6-711854FAEC14 Q26830931-2B01B299-20CD-4F58-80A7-5FB2C3FE5F76 Q26851526-D9EF70A3-3E7F-4329-B1B9-28AC3DAE0752 Q27024106-5ADACCF4-F03F-4082-BAFC-B911ACC42107 Q28070214-B07180BC-3980-4FDE-A7BB-629138F2D1B8 Q34042627-7654C43D-0194-4F8D-AB36-007FD123A4E2 Q34438411-6AFA7502-CC98-4459-BC4C-26E97AA228F6 Q34582640-5F7A252E-5713-44EA-8B56-DB4CD52C723E Q34853959-925EC44B-A872-474F-9EEF-BE368B53240F Q35231246-29A4A6CB-B086-4BC6-BCA8-A76CB0812F28 Q36218717-A02D866D-E780-4143-B082-3FC6E9CBAAD3 Q36268306-09A79D01-0D2E-4EED-8B15-49FAEABF07EA Q36476394-3D5277ED-E5ED-4754-B6E8-089A6E4FADD3 Q36692838-94BBCFD8-AA54-40D9-9E34-83717FFA10E1 Q36843741-A6A7B0BA-FB59-4FEE-8520-011CD3E585D5 Q36850457-D1B69D2E-3684-417D-BE0F-84D1F8723598 Q37222176-75D8FA23-EB47-4F87-A259-DAFD6BCDA9D9 Q37295411-07CE6219-A36E-44AF-8803-B46538BB013A Q37690959-FC6C251B-C331-4345-9FA4-0879DB5AAAE9 Q38124064-D200AF47-818B-42EF-97E4-482553670E83 Q38181176-8A64AAD3-3CAE-493B-AAA1-4269C4DF4EF0 Q38271879-66881FAA-00F6-4EB5-80CE-BEFFF3F5EA49 Q38657642-A18F56FB-F867-4C52-9855-0FE37C8F22BB Q38727470-90B3CDAB-69D7-4034-9A1B-6C5F21FD781A Q38848213-6D49F2D1-3894-4F43-943E-0FC17CDEBEB3 Q39043844-C36CD8AB-8A67-43FE-B511-0CBFCE8F0B13 Q39377049-F3D07588-D991-40D8-AC5C-28B2C8309503 Q40485110-AE06DB77-62DE-4BA8-BC73-464A4AF3B3D7 Q41510005-04408BCE-9510-44A7-8F57-2F2D073E492C Q41785872-F0EF8765-C1A8-4CE2-A66B-179C58FCA5BB Q41930681-2BCE26C5-5A81-4FB0-8361-7176260AC460 Q41997055-E6EDA710-5ECC-4349-B35D-B6A263D7430E Q42969291-5DBF0DD3-578C-4963-90B5-6D076BFFF361 Q43147493-9B4C5817-083D-440D-BB81-BD429472622A Q44546985-3C858263-1627-4420-859F-6984B7D3C1FB Q46189367-0E2935BD-9619-4967-80FF-BE6190B66B95 Q47547584-912032E6-FC8D-4B9E-8987-D85FC472551C Q47936526-D2DC9D28-5CF6-4DCA-866B-C3329916F3A0 Q49544289-D7257A83-2C44-4EC8-8FFB-5020FAECE185 Q49884762-C4CB36DF-16BA-4501-B289-02579E6371D6

P2860

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer

http://www.wikidata.org/entity/Q36632306

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Topical TLR7 agonist imiquimod ...... in patients with breast cancer

@ast

Topical TLR7 agonist imiquimod ...... in patients with breast cancer

@en

type

label

Topical TLR7 agonist imiquimod ...... in patients with breast cancer

@ast

Topical TLR7 agonist imiquimod ...... in patients with breast cancer

@en

prefLabel

Topical TLR7 agonist imiquimod ...... in patients with breast cancer

@ast

Topical TLR7 agonist imiquimod ...... in patients with breast cancer

@en

P1433

Q36632306-F9595AB0-6ABA-4BBB-A9D6-0BD6306F7B0E

P1476

Q36632306-EE3205A1-E74F-443D-A343-23712A8ED3A4

P2093

Q36632306-03D1760C-3C4A-4CFD-8138-48BFB084FA5F

Q36632306-0B995FB1-46F1-48D2-94DB-9EBE24BED88C

Q36632306-0D3D9CB4-63EE-4D97-AB61-447F327C602A

Q36632306-2D196977-07B9-4478-9976-3366DB9BBA09

Q36632306-55AE212F-E989-487D-82D1-E9D2459A183F

Q36632306-7746D6ED-3A3A-4795-A858-EBEAED0F1FD5

Q36632306-953204EB-2143-4C90-9C40-57FE27ED5AD6

Q36632306-B72F7F82-F08D-4447-A2C3-E868A890805F

Q36632306-DB3D491F-4BE5-4241-B094-045DF0DBE798

Q36632306-E4608599-3CCA-450A-9064-A7CEA9116C8D

P2860

Q36632306-0237CD7B-63D7-40A2-997B-F6663DF1995A

Q36632306-093E22A5-7AB3-4842-A18E-A87679D6D716

Q36632306-1939F997-45BD-421F-BBEF-9030D5719F1A

Q36632306-296BAC13-7EFF-4E5E-B8F5-5FCAD7FE81AE

Q36632306-2A115116-ADB8-4739-9656-3BD1D2860B46

Q36632306-2E16A98B-6E96-4ED5-BC00-CD76FFD0438B

Q36632306-355357C6-C945-4A44-BEF7-9A1733A36FBE

Q36632306-3842951E-D031-48FA-9764-0C273131ABDC

Q36632306-4C592623-E70E-46AE-B266-D7B4706FBC31

Q36632306-50EF6B2B-40C5-4CD6-8C3F-6E50D8983AE2

P304

Q36632306-17D449C5-C358-4A83-A009-8A7803026F91

P31

Q36632306-4CFF5F62-0929-4FE3-B45A-12ACE48B1C6B

P356

Q36632306-52E0C927-C867-4A26-B7CE-D299BFCE1F60

P407

Q36632306-6350F3DE-12EE-4119-A37B-C3E2E9032A4D

P433

Q36632306-1686C6C3-976B-4D18-A8A1-5CB9512FDBD8

P478

Q36632306-111A74EB-2259-423F-969D-4D692751A5D9

P50

Q36632306-1522B669-AC61-44A3-AFA7-56C84D80253A

Q36632306-48CBF2C9-9D00-4EAE-89AB-5464366A1B91

Q36632306-57C456BC-3082-4089-BAED-29908BCA4178

Q36632306-8E0547CD-77D6-4B91-8E62-31C5468A9DD0

Q36632306-9142C5B6-36E2-4DC1-A725-C66F9354AF98

Q36632306-D63B21D9-2338-4748-BA4C-84BDA6E963C5

P577

Q36632306-088D1C4A-CBC0-4D3D-9813-3624BAF1641D

P698

Q36632306-E3FE16A5-6E02-40A8-BE1F-9E578858BBA2

P921

Q36632306-7CB72B6B-CBDF-4572-8F44-DC3AF32A4DC8

P932

Q36632306-931C5C59-506F-4EA2-B077-BF0C9D980701

P356

1078-0432.CCR-12-1149

P1433

Clinical Cancer Research

P1476

Topical TLR7 agonist imiquimod ...... in patients with breast cancer

@en

P2093

Amy Tiersten

http://www.w3.org/2001/XMLSchema#string

Derya Unutmaz

http://www.w3.org/2001/XMLSchema#string

Frank Martiniuk

http://www.w3.org/2001/XMLSchema#string

James Speyer

http://www.w3.org/2001/XMLSchema#string

Leonard Liebes

http://www.w3.org/2001/XMLSchema#string

Lina Kozhaya

http://www.w3.org/2001/XMLSchema#string

Nicholas Shuman

http://www.w3.org/2001/XMLSchema#string

Nina Bhardwaj

http://www.w3.org/2001/XMLSchema#string

Silvia C Formenti

http://www.w3.org/2001/XMLSchema#string

Tsivia Hochman

http://www.w3.org/2001/XMLSchema#string

P2860

TLR signaling pathways

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

The regulation of IL-10 production by immune cells

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Cutaneous metastasis: a meta-analysis of data.

Toll-like receptor agonists in cancer therapy.

Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratoses

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.

INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect.

P304

6748-6757

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-1149

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Judith D Goldberg

Deborah Axelrod

P577

2012-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22767669

http://www.w3.org/2001/XMLSchema#string

P921

Toll-like receptor

P932

3580198

http://www.w3.org/2001/XMLSchema#string